Li-Ling Tan1, Jeanette Ting1, Iswaree Balakrishnan1, Aruni Seneviratna1, Lingli Gong2, Mark Y Chan1,2,3, E Shyong Tai2,4, A Mark Richards1,2,3,5, Bee-Choo Tai6, Lieng-Hsi Ling1,2,3, Chi-Hang Lee1,2,3. 1. Department of Cardiology, National University Heart Centre Singapore, Singapore. 2. Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. 3. Cardiovascular Research Institute, National University Health System, Singapore. 4. University Medicine Cluster, National University Health System, Singapore. 5. Department of Medicine, University of Otago, Christchurch, New Zealand. 6. Saw Swee Hock School of Public Health, National University of Singapore, Singapore.
Abstract
STUDY OBJECTIVES: Sleep apnea is often newly diagnosed in patients presenting with ST-segment elevation myocardial infarction (STEMI). We assessed longitudinal changes in apnea-hypopnea index (AHI) and sleep apnea phenotype after STEMI and determined its association with changes in the left ventricular ejection fraction (LVEF). METHODS: A total of 101 eligible patients with STEMI underwent consecutive sleep studies and echocardiographic studies within 5 days of admission and at 6-month follow-up. Sleep apnea (AHI ≥ 15 events/h) was further divided into obstructive sleep apnea (OSA) or central sleep apnea (CSA). RESULTS: Both AHI (mean difference -6.4 events/h, 95% confidence interval [CI] -9.6 to 3.3, P < .001) and LVEF (mean difference 2.6%, 95% CI 1.3 to 4.0, P < .001) improved from baseline to 6 months. The improvement in AHI was associated with an increase in LVEF (β = -.47, 95% CI -.86 to -.07, P = .023) and a decrease in left ventricular end-systolic volume (LVESV) (β = .25, 95% CI .07 to .43, P = .007). Of the patients with OSA at baseline (46%), resolution of OSA was seen in 48% at 6 months. Of those with CSA at baseline (12%), conversion to OSA was seen in 83%. In contrast, among those with no sleep apnea (42%) at baseline, the diagnosis remained the same in 93% at 6 months. CONCLUSIONS: Concurrent changes in AHI, LVEF, and LVESV were seen after STEMI. Sleep studies performed on admission are reliable in excluding sleep apnea. However, patients with OSA or CSA on admission warrant re-evaluation due to evolution of the sleep apnea phenotype.
STUDY OBJECTIVES:Sleep apnea is often newly diagnosed in patients presenting with ST-segment elevation myocardial infarction (STEMI). We assessed longitudinal changes in apnea-hypopnea index (AHI) and sleep apnea phenotype after STEMI and determined its association with changes in the left ventricular ejection fraction (LVEF). METHODS: A total of 101 eligible patients with STEMI underwent consecutive sleep studies and echocardiographic studies within 5 days of admission and at 6-month follow-up. Sleep apnea (AHI ≥ 15 events/h) was further divided into obstructive sleep apnea (OSA) or central sleep apnea (CSA). RESULTS: Both AHI (mean difference -6.4 events/h, 95% confidence interval [CI] -9.6 to 3.3, P < .001) and LVEF (mean difference 2.6%, 95% CI 1.3 to 4.0, P < .001) improved from baseline to 6 months. The improvement in AHI was associated with an increase in LVEF (β = -.47, 95% CI -.86 to -.07, P = .023) and a decrease in left ventricular end-systolic volume (LVESV) (β = .25, 95% CI .07 to .43, P = .007). Of the patients with OSA at baseline (46%), resolution of OSA was seen in 48% at 6 months. Of those with CSA at baseline (12%), conversion to OSA was seen in 83%. In contrast, among those with no sleep apnea (42%) at baseline, the diagnosis remained the same in 93% at 6 months. CONCLUSIONS: Concurrent changes in AHI, LVEF, and LVESV were seen after STEMI. Sleep studies performed on admission are reliable in excluding sleep apnea. However, patients with OSA or CSA on admission warrant re-evaluation due to evolution of the sleep apnea phenotype.
Authors: Jordi de Batlle; Cecilia Turino; Alicia Sánchez-de-la-Torre; Jorge Abad; Joaquín Duran-Cantolla; R Douglas McEvoy; Nick A Antic; Olga Mediano; Valentín Cabriada; Maria José Masdeu; Joaquín Teran; Joan Valls; Ferran Barbé; Manuel Sánchez-de-la-Torre Journal: Eur Respir J Date: 2017-03-15 Impact factor: 16.671
Authors: Shahrokh Javaheri; Ferran Barbe; Francisco Campos-Rodriguez; Jerome A Dempsey; Rami Khayat; Sogol Javaheri; Atul Malhotra; Miguel A Martinez-Garcia; Reena Mehra; Allan I Pack; Vsevolod Y Polotsky; Susan Redline; Virend K Somers Journal: J Am Coll Cardiol Date: 2017-02-21 Impact factor: 24.094
Authors: Chi-Hang Lee; See-Meng Khoo; Mark Y Chan; Hwee-Bee Wong; Adrian F Low; Qian-Hui Phua; A Mark Richards; Huay-Cheem Tan; Tiong-Cheng Yeo Journal: J Clin Sleep Med Date: 2011-12-15 Impact factor: 4.062
Authors: Ferran Barbé; Alicia Sánchez-de-la-Torre; Jorge Abad; Joaquin Durán-Cantolla; Olga Mediano; Jose Amilibia; Maria José Masdeu; Marina Florés; Antonia Barceló; Mónica de la Peña; Albina Aldomá; Fernando Worner; Joan Valls; Gerard Castellà; Manuel Sánchez-de-la-Torre Journal: Eur Respir J Date: 2015-01-08 Impact factor: 16.671
Authors: Christoph Fisser; Kristina Götz; Andrea Hetzenecker; Kurt Debl; Florian Zeman; Okka W Hamer; Florian Poschenrieder; Claudia Fellner; Stefan Stadler; Lars S Maier; Michael Pfeifer; Stefan Buchner; Michael Arzt Journal: Clin Res Cardiol Date: 2020-06-09 Impact factor: 5.460